6-K - Sanofi | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Sanofi disclosed the termination of Paul Hudson as Chief Executive Officer effective February 17, 2026, with detailed compensation arrangements including pro rata variable pay, vested performance shares valued at €5.9M, a €5.2M termination benefit, and a €3.1M non-compete indemnity. Olivier Charmeil was appointed Interim CEO from February 18, 2026, and Belén Garijo's compensation policy as future CEO starting April 29, 2026, was outlined, featuring €1.6M fixed pay and 360,000 performance shares over four years.

Current Report Details

Event Type

6-K

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Other Event

Executive & Director Changes

Paul Hudson

Chief Executive Officer

Termination

Effective: 2026-02-17

Olivier Charmeil

Interim Chief Executive Officer

Appointment

Effective: 2026-02-18

Transitory following Paul Hudson termination

Belén Garijo

Chief Executive Officer

Appointment

Effective: 2026-04-29

Exhibits (1)

6-K